| Bioactivity | Ganitumab (AMG 479) is a recombinant human monoclonal antibody to the human type 1 insulin-like growth factor receptor (IGF1R). Ganitumab recognizes murine IGF1R with sub-nanomolar affinity (KD=0.22 nM) and inhibits the interaction of murine IGF1R with IGF1 and IGF2. Ganitumab can be used in research of cancer[1]. |
| Invitro | Ganitumab (AMG 479; 0.032-500 nM; 10 分钟; CT26 细胞) 结合 mIGF1R 并抑制 IGF1 和 IGF2 介导的 mIGF1R 的激活[1]。 Western Blot Analysis[1] Cell Line: |
| In Vivo | Ganitumab (AMG 479; 1 mg/剂; i.p; Naïve 和荷瘤小鼠) 抑制 IGF1 诱导的小鼠肺中 mIGF1R 的激活[1]。Ganitumab (300 μg/剂; i.p.; 雌性无胸腺裸鼠) 减少外周血中性粒细胞[1]。Ganitumab (300 μg/剂; i.p.;雄性无胸腺裸鼠) 导致雄性小鼠糖耐量受损，并增加血清中 mGH，mIGF1 和 mIGFBP3[1]。 Animal Model: |
| Name | Ganitumab |
| CAS | 905703-97-1 |
| Appearance | Liquid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Moody G, et, al. IGF1R blockade with ganitumab results in systemic effects on the GH-IGF axis in mice. J Endocrinol. 2014 Mar 17;221(1):145-55. |